THURSDAY, JUNE 26
Session 1: 8:40 - 10:30 AM
Cardiogenic Shock is a continuum: learnings from the most recent studies
Moderators: Susanna Price (London, GBR), Phyllis Billia (Toronto, CAN), Stavros Drakos (Salt Lake City, USA)
Room : Auditorium
Continuum from Pre-shock to Shock – Erin Bohula (Boston, USA)
Serial Shock Assessment – Shashank Sinha (Falls Church, USA)
Biological Phenotypes are Key – Sabri Soussi (Toronto, CAN)
Devices Are Here to Stay – Pascal Le Prince (Paris, FRA) Universal Definition of CS: Are We Ready? – Alessandro Sionis (Barcelona, ESP) We Can Still Improve CS Trial Design – Antoine Kimmoun (Nancy, FRA) Industry perspective - Abiomed PMDA point of view
Panel discussion with all the above
Additional panelist : Pietro Di Santo ( Ottawa, CAN)
Medical Rapporteurs : Antoine Kimmoun (Nancy, FRA), Pablo Sanchez (San Francisco, USA)
Session 2: 11:00 AM - 12:30 PM
Enriching the studied population to achieve “positive” RCTs
Moderators: David Baran (Fort Lauderdale, USA), Janine Pöss (Leipzig, DEU), Antoine Herpain (Brussels, BEL)
Invasive Hemodynamics remains key – Jan Belohlavek (Prague, CZE) Novel Biomarkers – Francesca Manicone (Brussel, BEL) Gender is key: learnings from ECLS-Shock – Uwe Zeymer (Ludwigshafen, DEU) Altshock2 – Guido Tavazzi (Pavia, ITA) Learnings from a large database – David Morrow (Boston, USA) New insights on Cardiogenic Shock Management in Japan - Naoki Sato (Tokyo, JAP)
Regulatory point of view - Maciej Kostrubiec (EMA, POL)
Panel discussion with all the above
Additional panelist : Pietro Di Santo ( Ottawa, CAN)
Medical Rapporteurs : Pietro Di Santo (Ottawa,CAN), Thomas Hanff (Salt Lake City, USA)
Session 3A: 1:30 - 2:30 PM
Ongoing trials in cardiogenic shock
Moderators: Hannah Schaubroeck (Brussels, BEL), Carlos Alviar (New York, USA)
Pre-recorded presentations: Procard 1B – Alexandre Mebazaa (Paris, FRA) INTeGRATE – Biykem Bozkurt (Houston, USA) DOREMI 2 – Rebecca Matthew (Ottawa, CAN) SEISMIC C – Matteo Pagnesi (Brescia, ITA) EmpaShock – Antoine Kimmoun (Nancy, FRA) Unload VA-ECMO + Impella – Dirk Westermann (Freiburg, DEU) LevoHeartShock – Bruno Levy (Nancy, FRA) CERAMICS – Mir Babar Basir (Detroit, USA) PACCS – Manreet Kanwar (Pittsburgh, USA) IV-cangrelor STEMI shock – Sarah Gorgis (Cleveland, USA) Dobermann - Sarah Holle (Copenhagen, DEN)
Panel discussion with all the above
Medical Rapporteurs : Florian Wenzl (Zürich, CHE), Sarah Holle (Copenhagen, DEN)
Session 4: 2:30 - 4:00 PM
Cardiogenic shock : Joined efforts of regulators and trialist to achieve successful RCTs
Moderators: Monat Fiuzat (Arlington, USA), Uwe Zeymer (Ludwigshafen, DEU), Naoki Sato (Tokyo, JPN)
Here is urgent need for successes in CS trials – Jacob Moller (Odense, USA)
In post- AMI patients – Holger thiele (Leipzig, DEU)
In post- advanced heart failure patients – Mandeep Mehra (Harvard, USA)
We may match QOL and hard endpoints – Beth Davinson (Momentum Research, USA)
Mixed Shock: Ready for prime time ? – David Morrow (Boston, USA)
Restoring safely systolic blood pressure is double! – Jan Biegus (Wroclaw, POL)
Industry perspective: Steven Simonson (WindTree Tx, USA), Abiomed
Regulatory point of view - Fred Senatore (FDA, USA)
Panel discussion with all the above
Medical Rapporteurs: Ross Thomson (London, GRB)
Session 5: 4:30 - 5:40 PM
AI will change the future of ICU
Moderators: Alexandre Mebazaa (Paris, FRA), Michelle Chew (Linköping, SWE)
Use of artificial intelligence in critical care: opportunities and obstacles – Michael R Pinsky (Pittsburgh, USA)
Europe “INDICATE”s the ICU of the future – Christian Jung (Düsseldorf, DEU)
ICU patients already benefit from AI – Gilles Clermont (Pittsburgh, USA)
Regulatory point of view - Maciej Kostrubiec (EMA, POL)
Panel discussion with all the above
Additional Panelist : Jordan Pomeroy (FDA, USA)
CONFERENCE DINNER : 7:30 - 9:30 PM
FRIDAY, JUNE 27
Session 6A: 8:30 - 10:00 AM
Acute heart failure: ready for personalized post-discharge
Moderators: Christopher O'Connor (Fairfax, USA), Ileana Piña (Philadelphia, USA)
Trial design to assess GDMT implementation – Harriette Van Spall (Hamilton, CAN)
Devices and GDMT: the recipe for success – Biykem Bozkurt (Houston, USA)
Modulating inflammation paths - Gad Cotter (Momentum Research, USA)
MRA is reborn, what next? – Harriette Van Spall (Hamilton, CAN)
Biomarkers to allow patients empowerment – Carolyn Rosner (Falls Church, USA)
Industry Perspective - Léa Ricci (Roche), Katja Rohwedder (Bayer, USA), Medtronic
Panel discussion with all the above
Medical Rapporteurs: Jolie Bruno (Berne, SUI)
Session 7A: 10:30 AM - 12:00 PM
Life-threatening pulmonary hypertension: Hurray! there are successful trials
Moderators: Vallerie McLaughlin (Ann Arbor, USA), Arianna Colosio (Lancet Respiratory Medicine, GBR)
PMDA perspective on the novel therapies in PAH
Novelties in PAH and right ventricular dysfunction – Anna Hemnes (Nashville, USA)
Successes in life-threatening PAH: what secrets? – Laurent Savale (Paris, FRA)
Endotyping PAH is the future – Athénaïs Boucly (Paris, FRA)
Ongoing trials in life-threatening PAH – Vallerie McLaughlin (Ann Arbor, USA)
Novelties in acute pulmonary embolism – Riyaz Bashir (Philadelphia, USA)
Industry Perspective, Patients Perspective : Ramon Pediani (AOP Health), Sanjay Shrivastava (Innova Vascular)
Regulatory point of view - Maciej Kostrubiec (EMA, POL)
Panel discussion with all the above
Additional Panelist : Mitchell Psotka (FDA, USA)
Medical Rapporteurs - Athenaïs Boucly (Paris, FRA), Deborah Gorth (Philadelphia, USA)
Session 8A: 1:00 - 3:00 PM
New directions in ARDS trials
Moderators: Arianna Colosio (Lancet Respiratory Medicine, GBR), Taylor Thompson (Boston, USA)
Phase 3 trial assessing stem cell product MultiStem® - Eric Jenkins (Bellevue, USA)
Real-time biomarker measures in ARDS is doable - Daniel Clark Files (Wake Forrest, USA)
The PANTHER trial: First biomarker-guided trial in ARDS - Neil Aggarwal (Denver Colorado, USA)
The DRIVE trial - Sarina Sahetya (Baltimore, USA)
Biology studies in the Panther Trial – Narges Alipanah-Lechner (San Francisco, USA)
Patient perspective - Eileen Rubin (Chicago, USA)
Lessons from the ongoing ADCAP trial: enriching for more severe patients - Axel Vater (Aptarion Biotech, DEU)
Industry Perspective - Negin Hajizadeh (Bayer, USA)
Panel discussion with all the above Additional panelist : Derek Russel (Birmingham, USA)
Medical Rapporteurs - Narges Alipanah-Lechner (San Francisco, USA), Charles de Roquetaillade (Paris, FRA)
Session 9A: 3:30 - 5:00 PM
Sepsis: ongoing trials testing new targets
Moderators: Wes Self (Nashville, USA), Michele Chew (Malmö, SWE), Claudia Dos Santos (Toronto, CAN)
Disseminated intravascular coagulation: pathophysiology - Jerrold Levy (Durham, USA)
Disseminated intravascular coagulation: novel target – Nicole Juffermans (Amsterdam, NLD)
Immune Dysregulation – Purvesh Khatri (San Francisco, USA)
Immunology – Benjamin Chousterman (Paris, FRA)
Vasopressors – Ashish K. Khanna (Wake Forest, USA)
Pre-shock sepsis: phenotype matters – Nathan Shapiro (Groton, USA)
Together we can dramatically improve the burden of sepsis - Jackie Duda (Frederick, USA)
Industry perspective - Bayer
PMDA Perspective on Sepsis and Septic Shock
